- Home
- North America Medicinal Chemistry For Drug Discovery Market
North America Medicinal Chemistry for Drug Discovery Market - Industry Trends and Forecast to 2029
- Published Date: January, 2022 | Report ID: CLS-28 | No of pages: 131 | Format:
North America medicinal chemistry for drug discovery market is projected to register a substantial CAGR of 14.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
North America Medicinal Chemistry For Drug Discovery Market By Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization, Candidate Validation), Design (Fragment-Based Variation, Structure-Based Drug Design, Diversity Oriented Synthesis, Chemogenomics, Natural Products, Others), Drug Type (Small Molecules, Biologics), Therapeutic Area (Oncology, Neurology, Infectious and Immune System Diseases, Cardiovascular Diseases, Digestive System Diseases, Others), End User (Contract Research Organization, Pharmaceuticals and Biotechnology Companies, Academic and Research Institutes, Others), By Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the North America medicinal chemistry for drug discovery market are:
Increase in research and development investment for discovery and development of novel drug molecules
Initiatives for research on rare diseases and orphan drugs
Market Players:
The key market players for North America medicinal chemistry for drug discovery market are listed below:
Eurofins Scientific
Labcorp Drug Development
WuXi AppTec
Pfizer Inc.
Sygnature Discovery
Bio Blocks Inc
Thermo Fisher Scientific, Inc.
Charles River
Piramal Pharma Solutions
Certara Inc
Drug Discovery Alliances
Genscript Biotech
Nanosyn
Aurigene Pharmaceutical Services
NEREID THERAPEUTICS
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 OVERVIEW OF NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET 13
1.4 CURRENCY AND PRICING 15
1.5 LIMITATIONS 15
1.6 MARKETS COVERED 16
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 DBMR TRIPOD DATA VALIDATION MODEL 21
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 24
2.6 MULTIVARIATE MODELLING 25
2.7 MARKET END USER COVERAGE GRID 26
2.8 PROCESS LIFELINE CURVE 27
2.9 DBMR MARKET POSITION GRID 28
2.10 VENDOR SHARE ANALYSIS 30
2.11 SECONDARY SOURCES 31
2.12 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 PESTEL ANALYSIS 36
4.2 POTERS FIVE FORCES 37
5 NORTH AMERICA MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET: REGULATIONS 38
6 MARKET OVERVIEW 40
6.1 DRIVERS 42
6.1.1 INCREASE IN R&D FOR DISCOVERY AND DEVELOPMENT OF NOVEL DRUG MOLECULES 42
6.1.2 RISE IN CHRONIC DISEASES 42
6.1.3 INITIATIVES FOR RESEARCH ON RARE DISEASES AND ORPHAN DRUGS 43
6.1.4 GROWTH IN BIOLOGICS 44
6.1.5 COLLABORATIONS AMONG RESEARCHERS AND PHARMACEUTICAL INDUSTRIES 44
6.2 RESTRAINTS 45
6.2.1 RISE IN COST OF FORMULATED DRUG 45
6.2.2 TECHNICAL RISKS IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 45
6.2.3 BIOETHICAL ISSUES IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 45
6.3 OPPORTUNITIES 46
6.3.1 ADVANCEMENTS IN BIOCHEMICAL, TRANSLATIONAL, AND MOLECULAR STUDIES 46
6.3.2 RISE IN HEALTHCARE EXPENDITURE 46
6.3.3 USE OF ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY FOR DRUG DISCOVERY 47
6.4 CHALLENGES 47
6.4.1 BIOLOGICS NEED SPECIALIST TESTING SERVICES 47
6.4.2 STRINGENT REGULATIONS 48
7 IMPACT OF COVID-19 ON NORTH AMERICA MEDICINAL CHEMISTRY IN DRUG DISCOVERY MARKET 49
7.1 IMPACT ON PRICE 49
7.2 IMPACT ON DEMAND 49
7.3 IMPACT ON SUPPLY CHAIN 50
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 50
7.5 CONCLUSION 51
8 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY PROCESS 52
8.1 OVERVIEW 53
8.2 TARGET SELECTION 56
8.3 TARGET VALIDATION 56
8.4 HIT-TO-LEAD IDENTIFICATION 56
8.5 LEAD OPTIMIZATION 57
8.6 CANDIDATE VALIDATION 57
9 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DESIGN 58
9.1 OVERVIEW 59
9.2 FRAGMENT-BASED VARIATION 62
9.3 STRUCTURE BASED DRUG DESIGN 62
9.4 DIVERSITY ORIENTED SYNTHESIS 63
9.5 CHEMOGENOMICS 63
9.6 NATURAL PRODUCTS 63
9.7 OTHERS 64
10 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY DRUG TYPE 65
10.1 OVERVIEW 66
10.2 SMALL MOLECULES 69
10.3 BIOLOGICS 69
11 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 70
11.1 OVERVIEW 71
11.2 ONCOLOGY 74
11.3 NEUROLOGY 74
11.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES 75
11.5 CARDIOVASCULAR DISEASES 75
11.6 DIGESTIVE SYSTEM DISEASES 76
11.7 OTHERS 76
12 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY END USER 77
12.1 OVERVIEW 78
12.2 CONTRACT RESEARCH ORGANIZATION 81
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 81
12.4 ACADEMIC AND RESEARCH INSTITUTES 81
12.5 OTHERS 82
13 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET, BY COUNTRY 83
13.1 OVERVIEW 83
13.1.1 U.S. 87
13.1.2 CANADA 89
13.1.3 MEXICO 91
14 NORTH AMERICA MEDICINAL CHEMISTRY FOR DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 93
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 93
15 SWOT ANALYSIS 94
16 COMPANY PROFILE 95
16.1 EUROFINS SCIENTIFIC 95
16.1.1 COMPANY SNAPSHOT 95
16.1.2 REVENUE ANALYSIS 96
16.1.3 COMPANY SHARE ANALYSIS 96
16.1.4 SERVICE PORTFOLIO 96
16.1.5 RECENT DEVELOPMENT 97
16.2 LABCORP DRUG DEVELOPMENT 98
16.2.1 COMPANY SNAPSHOT 98
16.2.2 REVENUE ANALYSIS 99
16.2.3 COMPANY SHARE ANALYSIS 99
16.2.4 SERVICE PORTFOLIO 100
16.2.5 RECENT DEVELOPMENT 100
16.3 CHARLES RIVER 101
16.3.1 COMPANY SNAPSHOT 101
16.3.2 REVENUE ANALYSIS 101
16.3.3 COMPANY SHARE ANALYSIS 102
16.3.4 SERVICE PORTFOLIO 102
16.3.5 RECENT DEVELOPMENTS 102
16.4 WUXI APPTEC 103
16.4.1 COMPANY SNAPSHOT 103
16.4.2 REVENUE ANALYSIS 103
16.4.3 COMPANY SHARE ANALYSIS 104
16.4.4 SERVICE PORTFOLIO 104
16.4.5 RECENT DEVELOPMENTS 104
16.5 EVOTEC SE 105
16.5.1 COMPANY SNAPSHOT 105
16.5.2 REVENUE ANALYSIS 105
16.5.3 COMPANY SHARE ANALYSIS 106
16.5.4 SERVICE PORTFOLIO 106
16.5.5 RECENT DEVELOPMENTS 106
16.6 THERMO FISHER SCIENTIFIC INC. 107
16.6.1 COMPANY SNAPSHOT 107
16.6.2 REVENUE ANALYSIS 107
16.6.3 SERVICE PORTFOLIO 108
16.6.4 RECENT DEVELOPMENT 108
16.6.4.1 ACQUISITION 108
16.7 AURIGENE PHARMACEUTICAL SERVICES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES) 109
16.7.1 COMPANY SNAPSHOT 109
16.7.2 REVENUE ANALYSIS 109
16.7.3 SERVICE PORTFOLIO 110
16.7.4 RECENT DEVELOPMENT 110
16.8 BIOBLOCKS INC 111
16.8.1 COMPANY SNAPSHOT 111
16.8.2 SERVICE PORTFOLIO 111
16.8.3 RECENT DEVELOPMENT 111
16.9 CERTARA INC 112
16.9.1 COMPANY SNAPSHOT 112
16.9.2 REVENUE ANALYSIS 112
16.9.3 SERVICE PORTFOLIO 113
16.9.4 RECENT DEVELOPMENTS 113
16.10 DRUG DISCOVERY ALLIANCES 114
16.10.1 COMPANY SNAPSHOT 114
16.10.2 SERVICE PORTFOLIO 114
16.10.3 RECENT DEVELOPMENT 114
16.11 GENSCRIPT BIOTECH 115
16.11.1 COMPANY SNAPSHOT 115
16.11.2 REVENUE ANALYSIS 115
16.11.3 SERVICE PORTFOLIO 116
16.11.4 RECENT DEVELOPMENT 116
16.12 JUBILANT BIOSYS 117
16.12.1 COMPANY SNAPSHOT 117
16.12.2 SERVICE PORTFOLIO 117
16.12.3 RECENT DEVELOPMENTS 117
16.13 NANOSYN 119
16.13.1 COMPANY SNAPSHOT 119
16.13.2 PRODUCT PORTFOLIO 119
16.13.3 RECENT DEVELOPMENT 119
16.14 NEREID THERAPEUTICS 120
16.14.1 COMPANY SNAPSHOT 120
16.14.2 SERVICE PORTFOLIO 120
16.14.3 RECENT DEVELOPMENT 120
16.15 PFIZER INC. 121
16.15.1 COMPANY SNAPSHOT 121
16.15.2 REVENUE ANALYSIS 121
16.15.3 SERVICE PORTFOLIO 122
16.15.4 RECENT DEVELOPMENTS 122
16.16 SELVITA 123
16.16.1 COMPANY SNAPSHOT 123
16.16.2 REVENUE ANALYSIS 123
16.16.3 SERVICE PORTFOLIO 124
16.16.4 RECENT DEVELOPMENTS 124
16.16.4.1 ACQUISITION 124
16.17 SPECTRIS PLC 125
16.17.1 COMPANY SNAPSHOT 125
16.17.2 REVENUE ANALYSIS 125
16.17.3 SERVICE PORTFOLIO 126
16.17.4 RECENT DEVELOPMENT 126
16.18 SYGNATURE DISCOVERY 127
16.18.1 COMPANY SNAPSHOT 127
16.18.2 SERVICE PORTFOLIO 127
16.18.3 RECENT DEVELOPMENTS 127
17 QUESTIONNAIRE 128
18 RELATED REPORTS 131
Segmentation
Short Description
North America medicinal chemistry for drug discovery market, By Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization, Candidate Validation), Design (Fragment-Based Variation, Structure-Based Drug Design), Diversity Oriented Synthesis, Chemogenomics, Natural Products, Others),Drug Type (Small Molecules, Biologics), Therapeutic Area (Oncology, Infectious And Immune System Disease, Neurology, Cardiovascular Disease, Digestive System Disease, Others), End User (Contract Research Organization, Academic And Research Institutes, Pharmaceutical & Biotechnology Companies, Others), Geography (U.S., Canada, Mexico) Industry Trends & Forecast to 2029.
Market Definition:
Medicinal chemistry is the interdisciplinary field of science that involves a team of scientists (including synthetic organic chemists, analytical chemists, biologists, toxicologists, pharmacologists, microbiologists, and bio pharmacists) working together for drug discovery, design, development and synthesis of new pharmaceuticals. Moreover, the contribution of medicinal chemistry is not confined just to the discovery stage. It carries its purpose along the entire spectrum of clinical development. Each and every stage of clinical development involves surplus amounts of formulated drugs for studying potential benefits in human trials. With time the chemical methods adopted for the discovery of the molecules have also undergone changes leading to the development of technologies such as combinatorial chemistry (combichem), microwave assisted organic synthesis (MAOS) and high-throughput (HTS) biological screening.
Market Segmentation:
North America medicinal chemistry for drug discovery market is categorized into five notable segment which is process, design, drug type, therapeutic area and end user.
On the basis of process, the North America medicinal chemistry for drug discovery market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. In 2022, target selection segment is expected to dominate the North America medicinal chemistry for drug discovery market as it is the first process from where the drug discovery begins and where the biological targets are selected in an area of unmet medical needs.
On the basis of design, the North America medicinal chemistry for drug discovery market is segmented into fragment-based variation, structure-based drug design, diversity oriented synthesis, chemogenomics, natural products and others. In 2022, the fragment based variation segment is expected to dominate the North America medicinal chemistry for drug discovery market due to the fact that many potent compounds/ inhibitors of diverse targets have been developed using this method.
On the basis of drug type, the North America medicinal chemistry for drug discovery market is segmented into small molecules and biologics. In 2022, small molecules segment is expected to dominate the market due to the fact that as per the market study most of the drug discovery organizations are highly focused on small molecules discovery and less focused on biologics including proteins, peptides among others.
On the basis of therapeutic area, the North America medicinal chemistry for drug discovery market is segmented into oncology, infectious and immune system disease, neurology, cardiovascular disease, digestive system disease and others. In 2022, oncology segment is expected to dominate the market due to increasing prevalance of cancer and increasing number of clinical trials and research & development activities for development of novel therapeutics.
On the basis of end user, the North America medicinal chemistry for drug discovery market is segmented into contract research organization, academic and research institutes, pharmaceutical & biotechnology companies and others. In 2022, contract research organization is expected to dominate in the North America medicinal chemistry for drug discovery market because major market players signs collaborative agreement with contract research organizations for ongoing clinical trials in order to attain early drug development and approval.
Market Players
The key market players for North America medicinal chemistry for drug discovery market are listed below:
Eurofins Scientific
Labcorp Drug Development
WuXi AppTec
Pfizer Inc.
Sygnature Discovery
Bio Blocks Inc
Thermo Fisher Scientific, Inc.
Charles River
Piramal Pharma Solutions
Certara Inc
Drug Discovery Alliances
Genscript Biotech
Nanosyn
Aurigene Pharmaceutical Services
NEREID THERAPEUTICS
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.